Other languages Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
5.78 ^USD	+0.35%		+15.14%	-35.71%

May. 14	Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	CI
May. 07	Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	May. 14
Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	May. 07
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	May. 02
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	Apr. 30
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	Mar. 20
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	Mar. 07
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	Mar. 07
Sector Update: Health Care Stocks Higher Late Afternoon	Feb. 15
Sector Update: Health Care Stocks Higher Thursday Afternoon	Feb. 15
Sector Update: Health Care	Feb. 15
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	Feb. 15
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	Feb. 15
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	Feb. 15
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	Feb. 15
Kidney drug developer Aurinia fails to clinch a sale, sources say	Feb. 15
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	Feb. 14
Aurinia Pharmaceuticals Reports Higher Q4, 2023 Preliminary Revenue; Shares Rise	Jan. 05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Other languages

Filters